Gilenya Could Surpass Avonex Market Share, Analysts Say
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis' Gilenya is fresh out of the gate, but stands to collect a large share of the MS market, Leerink Swann analysts predict in a report.
You may also be interested in...
Emerging MS Treatments: Reading the Gilenya Tea Leaves
The closely watched launch of Gilenya, the first oral treatment for multiple sclerosis, may have changed the game for developing new therapies for the disease. Start-Up profiles four emerging MS drug developers: Allozyne, GeNeuro, Nuron Biotech and Receptos.
Biogen Continues To Plot New Course In Naming Two Key Executives – But Is Independence Part Of The Plan?
Since his arrival as CEO nearly seven months ago, Biogen Idec Inc.’s George Scangos has been exerting his influence in ways both big and small. None may have more lasting impact than his recruitment of two top industry executives, Steven Holtzman and Doug Williams, to take the reins respectively as Biogen’s executive VP of corporate development and executive VP of R&D.
Biogen Continues To Plot New Course In Naming Two Key Executives – But Is Independence Part Of The Plan?
Since his arrival as CEO nearly seven months ago, Biogen Idec Inc.’s George Scangos has been exerting his influence in ways both big and small. None may have more lasting impact than his recruitment of two top industry executives, Steven Holtzman and Doug Williams, to take the reins respectively as Biogen’s executive VP of corporate development and executive VP of R&D.